▶ FRAG 176-191 · SUBTOPIC · SAFETY PROFILE
FRAG 176-191 Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of FRAG 176-191.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of FRAG 176-191. Severity, frequency, and attribution depend on the source publication.
- Injection-site reactions
- Generally well-tolerated in published Phase 1/2 data
- No IGF-1 elevation (key distinction from rhGH or GH-axis peptides)
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for FRAG 176-191.
- No major drug-drug interactions documented in published data
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for FRAG 176-191 in the published record:
- Pregnancy/lactation (unstudied)
- Hypersensitivity
FDA REGULATORY STATUS
Not FDA-approved. Research-use only.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List (2026). Status reviewable annually.
SAFETY Q+A FROM LITERATURE
▶ Is Frag 176-191 FDA-approved?
No. Research-use only. The modified form (AOD-9604) was pursued by Metabolic Pharmaceuticals through Phase 2 obesity trials but did not progress to full approval.
▶ Is Frag 176-191 WADA-prohibited?
Frag 176-191 is not currently listed on the WADA Prohibited List as of 2026. The full HGH sequence is prohibited under Section S2; the lipolytic fragment is technically distinct due to the lack of IGF-1 elevation. Status reviewable annually.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Ng FM, Sun J, Sharma L, et al.. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000. PMID 10681682. link
- Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Invest 2013. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25